Acute Promyelocytic Leukemia

This is a type of acute myeloid leukemia where abnormal promyelocytes are the main type of white blood cell. Promyelocytes are immature white blood cells. This type of leukemia can cause blood clots to form in unusual places, which can be dangerous.

Condition

What people with Acute Promyelocytic Leukemia report

Every report comes from a Lived member, sent anonymously.

Have you tried Tretinoin for Acute Promyelocytic Leukemia?

NameHow it went

About Acute Promyelocytic Leukemia

What It Is

Acute promyelocytic leukemia (APL) is a fast-moving cancer of the blood and bone marrow and a distinct subtype of acute myeloid leukemia (AML). In APL, developing white blood cells called promyelocytes stop maturing and pile up in the marrow. They crowd out the healthy cells that fight infection, carry oxygen and help blood clot, which leads to tiredness, infections and easy bruising or bleeding. What sets APL apart from other leukemias is its effect on clotting. The leukemia cells set off a disorder in which the body uses up its clotting proteins and breaks clots down too quickly, so people can bleed seriously and, less often, form dangerous clots. That is why suspected APL is treated as a medical emergency. It is also why the outlook has changed so much: with prompt treatment, APL has gone from one of the most rapidly fatal leukemias to one of the most curable.

Causes & Risk Factors

APL starts with a genetic change that happens inside a bone marrow cell during a person's lifetime. Pieces of chromosomes 15 and 17 swap places, joining two genes into an abnormal fusion gene called PML::RARA. That gene blocks the normal maturing of promyelocytes, which is what lets the leukemia grow. Why the swap happens is usually unknown. APL can occur at any age but is most common in midlife. A small share of cases follow earlier chemotherapy or radiation for another illness, called therapy-related APL. Smoking and exposure to radiation or the chemical benzene raise the risk of AML in general, but most people with APL have no identifiable exposure, and nothing they did caused it.

How It's Diagnosed

APL often comes to light through a blood test done because of bruising, bleeding, tiredness, fever or infections. A complete blood count usually shows low platelets and low red cells, while the white cell count can be low or high. Clotting tests, including the level of fibrinogen (a protein the blood needs to form clots), show how severe the clotting problem is. Under the microscope, the abnormal promyelocytes in a blood smear or bone marrow sample have a characteristic look. The diagnosis is confirmed by finding the PML::RARA gene or the swap between chromosomes 15 and 17, using genetic tests on blood or bone marrow. Because those results can take time and bleeding can happen quickly, specialists start treatment as soon as APL is suspected, without waiting for confirmation. The white blood cell count at diagnosis also sets the risk group. A count of 10,000 cells per microliter of blood or lower is non-high risk; a count above that is high risk. The risk group mainly decides whether chemotherapy is added to the first phase of treatment.

Treatment Options

APL treatment works differently from most leukemia therapy. Instead of relying mainly on chemotherapy to kill cells, the core drugs push the leukemia cells to mature and die off. Tretinoin, also called all-trans retinoic acid (ATRA), is a pill related to vitamin A that acts on the PML::RARA problem and usually brings the clotting disorder under control quickly. Arsenic trioxide (Trisenox), given by IV infusion, both matures and destroys APL cells. In the first weeks, transfusions of platelets, plasma and clotting factors help prevent bleeding while these drugs take effect. For non-high-risk APL, ATRA plus arsenic trioxide without traditional chemotherapy is the standard. In a large trial, this combination brought remission in everyone who could be assessed and better two-year survival than ATRA with chemotherapy (99% versus 91%), with fewer infections and less suppression of blood counts. People with high-risk APL usually also receive chemotherapy early on, such as idarubicin, to bring the white count down quickly, followed by arsenic-based treatment. Treatment happens in phases. Induction, usually started in the hospital, aims to bring the leukemia into remission. Consolidation then continues for several months in cycles of weeks on and weeks off, often as an outpatient, to clear what remains. Some plans add lower-intensity maintenance treatment afterward. If APL comes back, arsenic-based treatment often brings a second remission, and a stem cell transplant may be considered. The key trade-off of ATRA and arsenic is differentiation syndrome, a reaction to the leukemia cells' rapid maturing that can cause fever, breathing trouble, fluid around the lungs, rapid weight gain and swelling. It can be life-threatening, so care teams watch for it closely and start steroids at the first sign, sometimes pausing the drugs. Arsenic can also disturb heart rhythm, so it requires regular electrocardiograms (ECGs) and keeping potassium and magnesium levels up. Tretinoin can cause serious birth defects and arsenic is unsafe at any stage of pregnancy, so pregnancy testing and reliable contraception are part of treatment, and APL during pregnancy needs a plan made jointly by the leukemia and obstetric teams.

What to Expect

The first weeks carry the greatest risk and the most intensive care. Most early deaths from APL are caused by bleeding, especially in the brain or lungs, before or soon after treatment begins. During this time, expect a hospital stay with daily blood tests, frequent transfusions and close watching for bleeding and differentiation syndrome. ATRA commonly causes headaches, dry skin and lips, and bone pain, and arsenic can raise liver test results; these are usually managed by adjusting care rather than stopping treatment. Once that early period passes, the outlook is very good. Most people who start treatment promptly reach remission, and in non-high-risk APL cure rates approach 100%. High-risk APL carries more early danger, but many people with it are also cured. Consolidation can be tiring, yet many people get through it largely as outpatients and gradually return to work and usual activities. After treatment ends, follow-up visits check blood counts. People with high-risk APL usually have periodic molecular tests that look for traces of PML::RARA, because catching a relapse early allows earlier treatment. For non-high-risk APL, where relapse is rare, guidelines consider this testing optional. Anyone who may want children should plan with the care team, since pregnancy should be avoided while taking ATRA or arsenic.

When to Seek Help

Unexplained bruising, tiny red or purple spots on the skin, or nosebleeds or bleeding gums that are hard to stop, especially alongside tiredness or fever, call for a blood test the same day rather than a routine appointment, because suspected APL is treated as an emergency. During treatment, call your care team right away for a new fever, shortness of breath, rapid weight gain or swelling, which can signal differentiation syndrome, or for fainting, dizziness or a racing or irregular heartbeat while receiving arsenic. Call 911 for a sudden severe headache, new confusion, weakness or numbness on one side of the body, coughing up blood, or bleeding that will not stop, since these can mean serious bleeding.

Questions to Ask Your Doctor

  1. 1.What is my risk group, and how does it shape my treatment plan?
  2. 2.Which parts of treatment will happen in the hospital, and how long will the whole course last?
  3. 3.Which signs of differentiation syndrome or bleeding should I watch for at home, and who do I call?
  4. 4.What follow-up testing will I need after treatment, and how will we know the leukemia is gone?
  5. 5.How could treatment affect pregnancy plans or fertility, and what contraception do I need?

Last reviewed • Oct 2026

Educational content, not medical advice.